Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).

Thomas CluzeauMarie SebertRamy Rahmé Stefania Cuzzubbo Jacqueline Lehmann-CheIsabelle MadelainePierre PeterlinBlandine BèveHabiba AttalahFatiha ChermatElsa MiekoutimaOdile Beyne RauzyChristian RecherAspasia StamatoullasLise WillemsEmmanuel RaffouxCéline BerthonBruno QuesnelMichael LoschiAntoine F Carpentier David A Sallman Rami S KomrokjiAnouk Walter-PetrichSylvie ChevretLionel AdesPierre Fenaux

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

In this very high-risk population of TP53m MDS and AML patients, eprenetapopt combined with AZA was safe and showed potentially higher ORR and CR rate, and longer OS than reported with AZA alone.

Keyphrases

acute myeloid leukemia
phase ii study
end stage renal disease
newly diagnosed
allogeneic hematopoietic stem cell transplantation
open label
peritoneal dialysis
randomized controlled trial
clinical trial
radiation therapy
rectal cancer
placebo controlled